Crandall Carolyn J, Aragaki Aaron, Cauley Jane A, Manson JoAnn E, LeBlanc Erin, Wallace Robert, Wactawski-Wende Jean, LaCroix Andrea, O'Sullivan Mary Jo, Vitolins Mara, Watts Nelson B
Department of Internal Medicine (C.J.C.), David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California 90095; Women's Health Initiative Clinical Coordinating Center (A.A.), Fred Hutchinson Cancer Research Center, Seattle, Washington 98109; Department of Epidemiology (J.A.C.), Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania 15213; Division of Preventive Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115; Center for Health Research NW (E.L.), Kaiser Permanente, Portland, Oregon 97227; Department of Epidemiology (R.W.), University of Iowa College of Public Health, Iowa City, Iowa 52242; Department of Epidemiology and Environmental Health (J.W.-W.), University at Buffalo, State University of New York, Buffalo, New York 14214; Public Health Sciences (A.L.), Fred Hutchinson Cancer Research Center, Seattle, Washington 98109; Department of Obstetrics and Gynecology (M.J.O'S.), Miller School of Medicine, University of Miami, Miami, Florida 33136; Department of Epidemiology and Prevention (M.V.), Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina 27157; and Mercy Health Osteoporosis and Bone Health Services (N.B.W.), Cincinnati, Ohio 45236.
J Clin Endocrinol Metab. 2015 Feb;100(2):524-34. doi: 10.1210/jc.2014-3062. Epub 2014 Dec 18.
Vasomotor symptoms (VMS) are common. Whether VMS are associated with fracture incidence or bone mineral density (BMD) levels is unknown.
This study aimed to examine associations of baseline VMS with fracture incidence and BMD.
This was a prospective observational study with mean (SD) followup of 8.2 (1.7) years (1993-2005).
Forty United States clinical centers.
We examined data from Women's Health Initiative Clinical Trial participants (n = 23 573) age 50-79 years not using menopausal hormone therapy, and 4,867 participants of the BMD sub-study.
None.
We measured baseline VMS, incident adjudicated fractures, and BMD (baseline, annual visits 1, 3, 6, and 9).
After adjustment for baseline age, body mass index, race/ethnicity, smoking, and education, the hazard ratio for hip fracture among women with baseline moderate/severe VMS (vs no VMS) was 1.78 (95% confidence interval [CI], 1.20-2.64; P = .01). There was no association between VMS and vertebral fracture. VMS severity was inversely associated with BMD during followup (P = .004 for femoral neck, P = .045 for lumbar spine). In repeated measures models, compared with women who reported no VMS, women with moderate/severe VMS had 0.015 g/cm(2) lower femoral neck BMD (95% CI, -0.025--0.005) and 0.016 g/cm(2) lower lumbar spine BMD (95% CI, -0.032--0.004).
Women with moderate/severe VMS have lower BMD and increased hip fracture rates. Elucidation of the biological mechanisms underlying these associations may inform the design of preventive strategies for at-risk women prior to occurrence of fracture.
血管舒缩症状(VMS)很常见。VMS是否与骨折发生率或骨矿物质密度(BMD)水平相关尚不清楚。
本研究旨在探讨基线VMS与骨折发生率及BMD之间的关联。
这是一项前瞻性观察性研究,平均(标准差)随访8.2(1.7)年(1993 - 2005年)。
美国40个临床中心。
我们研究了来自女性健康倡议临床试验参与者(n = 23573)的数据,这些参与者年龄在50 - 79岁,未使用绝经激素治疗,以及4867名BMD子研究的参与者。
无。
我们测量了基线VMS、经判定的新发骨折以及BMD(基线、第1、3、6和9年的年度随访)。
在对基线年龄、体重指数、种族/民族、吸烟和教育程度进行调整后,基线有中度/重度VMS的女性(与无VMS的女性相比)发生髋部骨折的风险比为1.78(95%置信区间[CI],1.20 - 2.64;P = 0.01)。VMS与椎体骨折之间无关联。在随访期间,VMS严重程度与BMD呈负相关(股骨颈P = 0.004,腰椎P = 0.045)。在重复测量模型中,与报告无VMS的女性相比,有中度/重度VMS的女性股骨颈BMD低0.015 g/cm²(95% CI, - 0.025 - - 0.005),腰椎BMD低0.016 g/cm²(95% CI, - 0.032 - - 0.004)。
有中度/重度VMS的女性BMD较低且髋部骨折发生率增加。阐明这些关联背后的生物学机制可能为高危女性在骨折发生前制定预防策略提供依据。